World-leading cancer treatment, research, and education center in Manhattan since 1884.
Memorial Sloan Kettering operates the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, opened in 2004, offering PhD and MD-PhD programs with a curriculum focused on cancer research. The institution trains approximately 1,700 medical residents and fellows, 575 postdoctoral researchers, and 288 combined PhD and MD-PhD candidates. The Tri-Institutional MD–PhD Program partners MSK with Weill Cornell Medicine and The Rockefeller University, leveraging proximity for collaborative biomedical research and training.
The Sloan Kettering Institute pursues basic and translational research across 9 programs and over 100 laboratories. MSK has pioneered major breakthroughs including CAR-T immunotherapy (FDA-approved 2017), the MSK-IMPACT tumor identification test (FDA-approved 2018), and G-CSF production methods (earning over $100 million in royalties). The institution maintains collaborative research centers and partnerships with leading academic institutions including Weill Cornell Medicine and Rockefeller University.
Located at 1275 York Avenue in Manhattan, MSK operates a 514-bed specialist cancer hospital treating approximately 400 types of cancer annually. Major facilities include the Mortimer B. Zuckerman Research Center (23-story, 100+ labs, opened 2006), David H. Koch Center for Cancer Care (opened 2020), Evelyn H. Lauder Breast Center (opened 2009), and Josie Robertson Surgery Center (opened 2015). MSK has expanded regionally to Westchester, Long Island, and New Jersey locations.
MSK is consistently ranked among the nation's top cancer centers and was rated an 'A' by Charity Watch in 2015. The institution was designated one of only three Comprehensive Cancer Centers nationwide when Congress passed the National Cancer Act of 1971. MSK received major philanthropic support including $400 million from David Geffen and Kenneth C. Griffin (2023) and $50 million from The Starr Foundation (2022).